Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Evalen 0.1% cream

Ferron Par Pharmaceuticals

Ingredients in every g

Adapalene 1 mg

Each package contains

1 tube of 10 g

Dosage form

cream

Dosage formCream

Flavour

None

W.H.O. classification

D10A
D10A

A.T.C. Level 1

Anatomical Main group

D - Dermatologicals
D10A

A.T.C. Level 2

Therapeutic subgroup

D10 - Anti-Acne Preparations
D10A

A.T.C. Level 3

Pharmacological subgroup

D10A - Anti-Acne Preparations for Topical Use

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

SAFE IF PRESCRIBEDThis item is safe for use while operating heavy machinery.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

CAUTIONThis item may not be safe for use during lactation. Use with caution and after consultation with your doctor.

Indication

Acne vulgaris
Evalen is used topically for the treatment of acne vulgaris

Dosage

12 YEARS OLD AND ABOVE
Evalen should be applied to affected areas of the skin, once daily in the evening before bedtime and after washing.

A thin film of Evalen should be applied, avoiding the eyes, lips, and mucous membranes. If product enters the eye, wash immediately with warm water. Ensure that the affected areas are dry before application.

During the early weeks of therapy with adapalene, an apparent exacerbation of acne may occur. This effect is attributable to the action of the drug on previously unseen lesions and should not be considered a reason to discontinue therapy.

Since it is customary to alternate therapies in the treatment of acne, it is recommended that the physician assess the continued improvement of the patient after three months of treatment with Evalen.

With patients for whom it is necessary to reduce the frequency of application or to temporarily discontinue treatment, frequency of application may be restored or therapy resumed once it is judged that the patient can again tolerate the treatment.